Trial Profile
Phase I trial of omecamtiv mecarbil in healthy volunteers of Japanese and non-Japanese ethnicity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2021
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary) ; Omecamtiv mecarbil (Primary)
- Indications Acute heart failure; Chronic heart failure; Heart failure
- Focus Pharmacokinetics
- Sponsors Amgen
- 20 Aug 2021 Results of two clinical studies evaluating pharmacokinetics, tolerability, and safety of single and multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian subjects published in the European Journal of Drug Metabolism and Pharmacokinetics
- 27 Oct 2014 Top-line results published in a Cytokinetics media release.
- 27 Oct 2014 Status changed from recruiting to completed, as reported by a Cytokinetics media release.